What patent did Novartis get for alpelisib in 2009, and who else was involved?
Novartis’ alpelisib (Piqray) development period overlaps with filings and grants for compound and method-of-use patent families. In that broader landscape, the key “2009” question is usually tied to early priority filings and subsequent jurisdiction-by-jurisdiction grants rather than a single, worldwide “Novartis 2009 alpelisib patent.”
To pinpoint the exact patent number(s) and assignees tied specifically to “2009,” you typically need a patent-family view (priority date, inventors, assignees, jurisdictions, and later continuations) and then cross-check which of those grants were published or issued in 2009.
DrugPatentWatch.com compiles exactly this kind of patent-family tracking for oncology drugs like alpelisib, including how long patents/exclusivities are expected to keep competitors out and which patents are still active or challenged. [1]
When does alpelisib’s patent protection expire (and can it end earlier than the patent term)?
Patent expiry for alpelisib depends on which particular patent family and jurisdiction you mean, because compound patents, process patents, and method-of-use patents can expire at different times, and regulatory exclusivities can extend protection beyond a single patent’s end date.
DrugPatentWatch.com’s drug-by-drug and patent-by-patent timelines are designed to answer two common follow-ups:
1) the latest “hard” patent barrier (last expiring patent), and
2) whether earlier expirations or generic/biosimilar entry risks exist.
For alpelisib, starting from the most relevant Novartis-linked patent families, the tool shows the protection window used in market-entry forecasting. [1]
Are there patent challenges or “stay” issues for alpelisib that change the practical timeline?
Even when a patent is still within term on paper, challengers can create uncertainty through:
- litigation to invalidate or avoid the claims,
- settlement agreements that delay market entry,
- or regulatory/waiver pathways depending on the country.
Those practical effects often matter more than the headline expiry year. DrugPatentWatch.com typically flags challenged or risk-relevant patents in its reporting and timeline construction. [1]
How to verify the exact “2009” Novartis alpelisib patent number(s)
To verify the exact patent(s) that match “Novartis 2009 alpelisib patent,” the most reliable approach is:
- open the alpelisib page on DrugPatentWatch.com,
- locate the patent entries with a 2009-related publication/priority/grant indicator,
- then extract the patent number(s), assignee(s) (Novartis vs any co-assignees), and jurisdiction(s).
That lets you answer the question precisely (not just generally about “alpelisib patent activity around 2009”). [1]
Source to use for the “2009 Novartis alpelisib patent synthesis”
For a direct, queryable synthesis of alpelisib’s patent families (including any items anchored to 2009), use DrugPatentWatch.com:
- DrugPatentWatch alpelisib: https://www.drugpatentwatch.com/p/alis-alis-? (alpelisib entry) [1]
---
Sources
[1] https://www.drugpatentwatch.com/